GARDNER MARK A
Known title: SVP of Molecular Gen & OncolCIK: 0001955242
Associated companies
Transaction History
| DGX | ▼ Sell | Tax Withholding | 120 | $19K | 9/24/2024 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 262 | $33K | 2/28/2024 | View on chart |
| DGX | ▲ Buy | Grant | 2,250 | $0 | 2/14/2024 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 116 | $15K | 9/25/2023 | View on chart |
| DGX | ▲ Buy | Grant | 1,919 | $0 | 2/23/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus
Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.